Visilizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Visilizumab
DrugBank Accession Number
DB12053
Background

Visilizumab has been investigated for the treatment of Ulcerative Colitis.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Visilizumab

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Visilizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Visilizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Visilizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Visilizumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Visilizumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Visilizumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Visilizumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Visilizumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Visilizumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Visilizumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
H18SKU3289
CAS number
219716-33-3

References

General References
Not Available
PubChem Substance
347911275
Wikipedia
Visilizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentAcute Myeloid Leukemia (AML) / Immunotherapy / Refractory Leukemia / Relapsed Adult AML1
3WithdrawnTreatmentIntravenous Steroid-Refractory Ulcerative Colitis1
2CompletedTreatmentCrohn's Disease (CD)2
2TerminatedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedTreatmentUlcerative Colitis1
2Unknown StatusTreatmentGraft Versus Host Disease (GVHD)1
2, 3CompletedTreatmentUlcerative Colitis1
2, 3TerminatedTreatmentUlcerative Colitis2
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 21:16 / Updated on February 21, 2021 18:53